-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
-
Summary
-
CRISPR Therapeutics AG annual/quarterly Depreciation, Depletion and Amortization history and growth rate from 2014 to 2024.
- CRISPR Therapeutics AG Depreciation, Depletion and Amortization for the quarter ending March 31, 2024 was $4.83M, a 4.32% decline year-over-year.
- CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2024 was $19.3M, a 2.91% decline from 2023.
- CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2023 was $19.8M, a 17.9% decline from 2022.
- CRISPR Therapeutics AG annual Depreciation, Depletion and Amortization for 2022 was $24.2M, a 34.6% increase from 2021.
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Growth (%)